CAR T Cell Therapy for Brain Cancer

This trial tests a new treatment for individuals with aggressive brain cancer that has returned or worsened. The treatment employs a special type of immune cell, called CAR T cells (Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells), modified to recognize and attack cancer cells in the brain. The main goal is to determine the safest dose and understand any side effects. This trial may suit someone who has had glioblastoma or a similar brain tumor and whose cancer has progressed after standard treatments. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial information does not specify if you need to stop taking your current medications. However, if you are on active bevacizumab therapy, you cannot participate in the trial. It's best to discuss your specific medications with the trial team.

Research has shown that the EGFR/IL13Rα2 pool-CAR T cell therapy is undergoing testing for safety when administered directly into the brain. Studies suggest that this delivery method is safe and feasible. Previous trials in brain cancer patients indicate that the treatment can be administered safely. However, similar CAR T cell therapies have reported serious side effects, including low blood pressure and fluid buildup in the lungs. As this is an early-stage trial, the treatment's safety remains under careful study. Participants should discuss these potential risks with their healthcare provider.¹²³⁴⁵

Unlike the standard treatments for brain cancer, which often include surgery, radiation, and chemotherapy, CAR T cell therapy offers a novel approach by using engineered immune cells to target cancer. This treatment is unique because it specifically targets EGFR and IL13Rα2, proteins commonly found on the surface of brain cancer cells, allowing for precise attacks on the tumor. Moreover, the delivery method via ICT and/or ICV catheter ensures that these specially designed T cells reach the brain directly, potentially leading to more effective results with fewer side effects. Researchers are excited about this therapy because it represents a shift from traditional methods, harnessing the body's own immune system to combat cancer cells in a targeted and potentially more effective way.

Studies have shown that CAR T cell therapy, which targets specific proteins called EGFR and IL13Rα2, holds promise for treating brain cancer, such as high-grade gliomas. Previous research found that delivering CAR T cells directly to the brain was feasible and helped shrink tumors. In this trial, participants will receive EGFR/IL13Rα2 pool-CAR T cells, which target two proteins simultaneously and have proven more effective than those targeting just one. Although the improvement in survival rates remains limited, early studies suggest this therapy might offer advantages over standard treatments. This CAR T cell therapy aims to enhance the immune system's ability to attack cancer cells in the brain more effectively.¹²³⁶⁷